Both domestically and abroad, the pharmaceutical and biotech sectors are feeling besieged on the IP front. Generic drug makers are challenging Big Pharma’s patents at the U.S. Patent and Trademark Office. So are hedge funds. Biotech patents also are under attack. And human rights groups are warning that the Trans-Pacific Partnership, a proposed trade deal between the U.S. and 11 other Pacific Rim countries, could end up favoring Big Pharma and make access to low-cost generic drugs in developing countries increasingly difficult.
But the pharmaceutical and biotech industries are not going to surrender easily to these attacks. In fact, they are aggressively fighting back.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
